PELATON and hepatocellular carcinoma: Kaplan–Meier analysis revealed that HCC patients in the high-SMIM25-expression group had significantly poorer relapse-free survival (RFS; HR = 3.37; 95% CI: 1.12−9.36) and overall survival (OS; HR = 2.13; 95% CI: 1.02−4.43) compared to those in the low-expression group (Figure 1F).